Abstract: The present invention relates to (R)-4-[5-(4-chlorophenyl)-1-[2-(trifluoromethyl)-phenyl]pyrrol-2-yl]-N-[2-(dimethylamino)-ethyl]benzamide (+)-L-tartrate salt, methods for its preparation, pharmaceutical compositions containing it and its use in treating diseases such as cancer.

Abstract: Holographic Video Microscopy analysis of non-spherical particles is disclosed herein. Properties of the particles are determined by application of light scattering theory to holography data. Effective sphere theory is applied to provide information regarding the reflective index of a sphere that includes a target particle. Known particles may be co-dispersed with unknown particles in a medium and the holographic video microscopy is used to determine properties, such as porosity, of the unknown particles.

Abstract: The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof, wherein: Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O; ring X is a benzene or pyridine ring; ring Y is a benzene, pyridine, thiophene or furan ring; Ar1 is an optionally substituted benzene, pyridine, thiophene or furan ring; m is 0, 1 or 2; n is 0, 1 or 2; R1 is selected from various substituents: R2 is selected from hydrogen and a C1-4 hydrocarbon group; R3 is selected from hydrogen and a C1-4 hydrocarbon group; R4 is selected from various substituents; R5 is selected from various substituents; Ar2 is an optionally substituted phenyl, pyridyl or pyridone group; R6 is a group Q1-Ra—Rb; Q1 is absent or is a C1-3 saturated hydrocarbon linker; Ra is selected from O; C(O); C(O)O; CONRc; N(Rc)CO; N(Rc)CONRc, NRc; and SO2NRc; Rb is selected from hydrogen and various substituents; and Rb is selec

Abstract: This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.

Abstract: The invention provides a composition of matter which: (i) consists of at least 90% by weight of an atropisomer (2A) and 0-10% by weight of an atropisomer of formula (2B); or (ii) consists of at least 90% by weight of an atropisomer (2B) and 0-10% by weight of an atropisomer of formula (2A); wherein the atropisomer of formula (2A) and the atropisomer of formula (2B) are represented by: or are pharmaceutically acceptable salts or tautomers thereof, wherein ring X is a benzene or pyridine ring; ring Y is selected from a benzene ring, a pyridine ring and a thiophene ring; R1 is trifluoromethyl; R2 is hydrogen; R3 is hydrogen; m is 0 or 1; n is 0, 1 or 2; Ar1 is a monocyclic aromatic ring selected from benzene and pyridine; each monocyclic aromatic ring being unsubstituted or substituted with 1 or 2 substituents R5 as defined herein; and R4; R5 when present, R6 and R7 independently selected from various substituents as defined herein.

Abstract: A cooking grill having a fire box with a cooking region and a panel at the rear or side of the cooking region of the firebox. The panel is adapted to support a shelf above the cooking region, the shelf having at least one prong extending therefrom. The panel has at least one aperture for receiving a respective prong of the shelf, and an abutment, for each aperture, positioned on the side of the panel remote from the cooking region and positioned with respect to its aperture to bear a respective prong of a shelf inserted through its aperture. Each prong of a shelf is inserted through an aperture such that a bottom part of the prong is supported by the periphery of the aperture and a top part of the prong bears upwardly against the abutment to support the shelf in a cantilevered fashion above the cooking region.

Abstract: The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof, wherein: Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O; ring X is a benzene or pyridine ring; ring Y is a benzene, pyridine, thiophene or furan ring; Ar1 is an optionally substituted benzene, pyridine, thiophene or furan ring; m is 0, 1 or 2; n is 0, 1 or 2; R1 is selected from various substituents: R2 is selected from hydrogen and a C1-4 hydrocarbon group; R3 is selected from hydrogen and a C1-4 hydrocarbon group; R4 is selected from various substituents; R5 is selected from various substituents; Ar2 is an optionally substituted phenyl, pyridyl or pyridone group; R6 is a group Q1-Ra—Rb; Q1 is absent or is a C1-3 saturated hydrocarbon linker; Ra is selected from O; C(O); C(O)O; CONRc; N(Rc)CO; N(Rc)CONRc, NRc; and SO2NRc; Rb is selected from hydrogen and various substituents; and Rb is selecte

Abstract: The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof, wherein: Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O; ring X is a benzene or pyridine ring; ring Y is a benzene, pyridine, thiophene or furan ring; Ar1 is an optionally substituted benzene, pyridine, thiophene or furan ring; m is 0, 1 or 2; n is 0, 1 or 2; R1 is selected from various substituents: R2 is selected from hydrogen and a C1-4 hydrocarbon group; R3 is selected from hydrogen and a C1-4 hydrocarbon group; R4 is selected from various substituents; R5 is selected from various substituents; Ar2 is an optionally substituted phenyl, pyridyl or pyridone group; R6 is a group Q1-Ra—Rb; Q1 is absent or is a C1-3 saturated hydrocarbon linker; Ra is selected from O; C(O); C(O)O; CONRc; N(Rc)CO; N(Rc)CONRc, NRc; and SO2NRc; Rb is selected from hydrogen and various substituents;

Abstract: A process for processing carbonaceous material, the process comprising: delivering a carbonaceous material to a reactor; delivering a catalyst to the reactor; processing the carbonaceous material at a relatively low temperature within the reactor to decompose the carbonaceous material to base compounds.

Abstract: Validating revisions of digital content managed by a content management system can include determining a quality metric value, the value indicating coverage of the digital content by a set of training data used to train a ranking model for ranking responses to search queries of the digital content. Additionally, content validation can include invoking a ranking editor in response to the quality metric value deviating from a predetermined threshold by more than a predetermined amount. Content validation can further include extending the set of training data using the interactive ranking editor.

Abstract: This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.

Abstract: Apparatus for modelocking a fiber laser cavity includes two variable retarder assemblies and a polarizing element. The variable retarder assemblies each have two electronically addressable elements and one fixed element. The first variable retarder assembly prepares a polarization state suitable for NPE modelocking to be launched into the fiber, and the second variable retarder assembly controls the polarization state after exiting the fiber, before being incident on the polarizing element. A control system controls the electronically addressable phase retarders in order to create and modify conditions for modelocking the fiber laser.

Abstract: Embodiments generally relate to selecting a service instance in a service infrastructure. In some embodiments, a method includes sending, by a service registry, a status request to each service instance of a plurality of service instances, where the service registry maintains a data store of performance information associated each of the service instances. The method further includes receiving, by the service registry, a plurality of status responses, where each status response is received from a respective service instance of the plurality service instances, and where each status response includes one or more performance characteristics. The method further includes ranking, by the service registry, the service instances based at least in part on the one or more performance characteristics. The method further includes performing, by the service registry, service lookups based on the ranking.

Abstract: This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.

Abstract: Embodiments generally relate to finding a service in a service infrastructure. In some embodiments, a method includes receiving a service lookup request, where the service lookup request includes an application program interface (API) specification for a service to be invoked, where the API specification defines at least one target input parameter and at least one target output parameter. The method further includes searching for at least one service that has an API specification that corresponds to the API specification included in the service lookup request. The method further includes determining a sequence of services if no service is found that has an API specification that corresponds to the API specification included in the service lookup request, where services of the sequence of services include API specifications that, in combination, correspond to the API specification included in the service lookup request; and invoking the services of the sequence of services.

Abstract: Apparatus for modelocking a fiber laser cavity includes two variable retarder assemblies and a polarizing element. The variable retarder assemblies each have two electronically addressable elements and one fixed element. The first variable retarder assembly prepares a polarization state suitable for NPE modelocking to be launched into the fiber, and the second variable retarder assembly controls the polarization state after exiting the fiber, before being incident on the polarizing element. A control system controls the electronically addressable phase retarders in order to create and modify conditions for modelocking the fiber laser.

Abstract: The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof, wherein: Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O; ring X is a benzene or pyridine ring; ring Y is a benzene, pyridine, thiophene or furan ring; Ar1 is an optionally substituted benzene, pyridine, thiophene or furan ring; m is 0, 1 or 2; n is 0, 1 or 2; R1 is selected from various substituents: R2 is selected from hydrogen and a C1-4 hydrocarbon group; R3 is selected from hydrogen and a C1-4 hydrocarbon group; R4 is selected from various substituents; R5 is selected from various substituents; Ar2 is an optionally substituted phenyl, pyridyl or pyridone group; R6 is a group Q1-Ra—Rb; Q1 is absent or is a C1-3 saturated hydrocarbon linker; Ra is selected from O; C(O); C(O)O; CONRc; N(Rc)CO; N(Rc)CONRc, NRc; and SO2NRc; Rb is selected from hydrogen and various substituents;

Abstract: The invention provides compound that inhibit or modulate the activity of p70S6 kinase, the compounds being of the formula (1): or a salt, tautomer or N-oxide thereof; wherein: one of Y and Z is R3 and the other is Ar2; Q1 is an optionally substituted C1-8 alkylene group; and wherein a carbon atom of the C1-8 alkylene group may optionally be replaced by a cyclopropane-1,1-diyl or cyclobutane-1,1-diyl group provided that the total number of carbon atoms in an alkylene group containing such a replacement does not exceed 8; Q2 is a bond or an optionally substituted C1-8 alkylene group R1 is selected from hydrogen, NRxRy and a group Cy1; Rx and Ry are each is selected from hydrogen, C1-4 hydrocarbyl or hydroxy-C1-4 hydrocarbyl; or NRxRy forms an optionally substituted 4 to 7-membered heterocyclic ring; Cy1 is an optionally substituted C-linked 3 to 7 membered monocyclic non-aromatic carbocyclic or heterocyclic; R2 and R4 are each is selected from hydrogen, fluorine, chlorine, optionally substituted C1-2 al

Abstract: Validating revisions of digital content managed by a content management system can include determining a quality metric value, the value indicating coverage of the digital content by a set of training data used to train a ranking model for ranking responses to search queries of the digital content. Additionally, content validation can include invoking a ranking editor in response to the quality metric value deviating from a predetermined threshold by more than a predetermined amount. Content validation can further include extending the set of training data using the interactive ranking editor.

Abstract: A cooking grill having a fire box with a cooking region and a panel at the rear or side of the cooking region of the firebox. The panel is adapted to support a shelf above the cooking region, the shelf having at least one prong extending therefrom. The panel has at least one aperture for receiving a respective prong of the shelf, and an abutment, for each aperture, positioned on the side of the panel remote from the cooking region and positioned with respect to its aperture to bear a respective prong of a shelf inserted through its aperture. Each prong of a shelf is inserted through an aperture such that a bottom part of the prong is supported by the periphery of the aperture and a top part of the prong bears upwardly against the abutment to support the shelf in a cantilevered fashion above the cooking region.